Woodstock Corp Boosts Stock Holdings in OmniAb, Inc. (NASDAQ:OABI)

Woodstock Corp lifted its holdings in shares of OmniAb, Inc. (NASDAQ:OABI) by 1.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 802,578 shares of the company’s stock after buying an additional 9,725 shares during the quarter. Woodstock Corp’s holdings in OmniAb were worth $2,841,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Palumbo Wealth Management LLC raised its holdings in OmniAb by 12.5% during the 3rd quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after acquiring an additional 2,744 shares during the period. Sei Investments Co. raised its stake in shares of OmniAb by 11.0% during the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock valued at $109,000 after purchasing an additional 2,888 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of OmniAb by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after purchasing an additional 8,909 shares during the period. CWC Advisors LLC. purchased a new stake in OmniAb during the 3rd quarter worth about $54,000. Finally, FMR LLC boosted its stake in OmniAb by 10.6% in the 3rd quarter. FMR LLC now owns 138,813 shares of the company’s stock worth $587,000 after purchasing an additional 13,324 shares during the period. 72.08% of the stock is currently owned by hedge funds and other institutional investors.

OmniAb Stock Performance

Shares of NASDAQ OABI opened at $3.18 on Friday. The stock’s 50-day simple moving average is $3.77 and its two-hundred day simple moving average is $4.07. OmniAb, Inc. has a twelve month low of $3.16 and a twelve month high of $6.55.

Analysts Set New Price Targets

OABI has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of OmniAb in a research report on Thursday, November 14th. Benchmark reaffirmed a “buy” rating and set a $8.00 target price on shares of OmniAb in a report on Thursday, November 14th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.